Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript

The other product has been sort of marketed for evaporative dry eye, whereas the concept is that VEVYE would be used for aqueous dry eye. And I would submit to you that if you’re a physician and you’re seeing a patient and you have to make a prescribing decision, most physicians, if not all of them, do not know whether a patient is experiencing evaporative or aqueous dry eye. And so our hope is that all things being equal, they will choose to have a product on board that can perform as our product performs that also contain cyclosporin, the highest concentration in the market. In terms of the data set that we presented, if you look at the 12-month sign and symptom improvement data, you’re talking about corneal staining data, improvement that is significant out of the gate.

Certainly within 4 weeks, within 1 month, you get total corneal fluorescein staining. Data improving massively and tear production also improving significantly, as well as the symptoms for the patients in terms of their dryness scores. And so if you look overall at this data set and you’re a prescriber, you can prescribe the highest concentration of cyclosporine and a product that not only works rapidly but has an extraordinary adverse event profile. And importantly, will last a long time in terms of the ability to improve signs and symptoms over a 52-week period. So we think we’re going to get quite a bit of those prescriptions certainly in the cyclosporin category. But our overall goal is, as I said earlier, to expand the market. And we think there are a lot of patients and a lot of prescribers that have wanted a product that can perform like VEVYE and they will soon have it.

Mayank Mamtani: Got it. Thanks for taking our questions.

Operator: I will now turn the call back over to Mark Baum for closing remarks.

Mark Baum: Sure. Thank you, Betsy. I’ve never been more confident in our prospects. I think the value of our company is far greater today than it ever has been. And we remain on track with a well-structured disciplined plan that is going to lead to the accomplishment of our goals, even though we may be a few months behind, the goals will be accomplished, we will get there. This is going to benefit not only our customers, the prescribers, but patients, our employees and our valued stockholders. So thanks to everyone for attending today’s call and your interest in Harrow. If you have any investor-related questions, please e-mail Jamie Webb at jwebb@harrowinc.com. This will conclude our call.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.